Calendrier des promotions Nuvectis Pharma, Inc.
Calendrier avancé
Graphique simple
À propos de l'entreprise Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company develops NXP800, a novel heat shock factor 1 pathway inhibitor for the treatment of various cancers; and NXP900, a small molecule drug candidate that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. plus de détails| IPO date | 2022-02-04 |
|---|---|
| ISIN | US67080T1088 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | usd |
| Сайт | https://www.nuvectis.com |
| Цена ао | 8.25 |
| Changement de prix par jour: | +3.98% (5.02) |
|---|---|
| Changement de prix par semaine: | +15.49% (4.52) |
| Changement de prix par mois: | -1.14% (5.28) |
| Changement de prix sur 3 mois: | -15.53% (6.18) |
| Changement de prix sur six mois: | -19.82% (6.51) |
| Changement de prix par an: | -37.41% (8.34) |
| Evolution du prix sur 3 ans: | 0% (5.22) |
| Evolution du prix sur 5 ans: | 0% (5.22) |
| Evolution des prix sur 10 ans: | 0% (5.22) |
| Evolution des prix depuis le début de l'année: | +5.45% (4.95) |
|
|
Sous-estimation
|
Efficacité
|
|||||||||||||||||||||||||||||||||||||
Dividendes
|
Devoir
|
Impulsion de croissance
|
|||||||||||||||||||||||||||||||||||||
| Établissements | Volume | Partager, % |
|---|---|---|
| Blackrock Inc. | 387891 | 2.18 |
| Vanguard Group Inc | 294283 | 1.66 |
| Baldwin Brothers, Inc. | 142040 | 0.8 |
| Geode Capital Management, LLC | 131657 | 0.74 |
| State Street Corporation | 118279 | 0.67 |
| Northern Trust Corporation | 61574 | 0.35 |
| Renaissance Technologies, LLC | 51800 | 0.29 |
| Millennium Management LLC | 34011 | 0.19 |
| Forbes, J.M. & Company | 34000 | 0.19 |
| GSA Capital Partners LLP | 27313 | 0.15 |
| ETF | Partager, % | Rentabilité pour l'année, % | Dividendes, % |
|---|---|---|---|
| iShares Micro-Cap ETF | 0.0153 | 17.09 | 1.54048 |
| Superviseur | Titre d'emploi | Paiement | Année de naissance |
|---|---|---|---|
| Mr. Ron Bentsur M.B.A. | Co-Founder, Chairman, CEO & President | 1.12M | 1966 (59 années) |
| Dr. Enrique Poradosu Ph.D. | Co-Founder, Executive VP, Chief Scientific & Business Officer | 705.5k | 1967 (58 années) |
| Mr. Shay Shemesh | Co-Founder, Executive VP, Chief Development & Operations Officer | 705.5k | 1984 (41 année) |
| Mr. Michael Carson CPA | Vice President of Finance | N/A | 1976 (49 années) |
Adresse: United States, Fort Lee. NJ, 1 Bridge Plaza - ouvrir dans Google Maps, ouvrir les cartes Yandex
Site web: https://www.nuvectis.com
Site web: https://www.nuvectis.com
